Keytruda Plus Inlyta Improves Survival Compared ot Sutent for Treatment of Advanced Kidney Cancer

Results from the randomized, phase III KEYNOTE-426 clinical trial show that first-line therapy with a combination of the PD-1 targeted immunotherapy Keytruda (pembrolizumab) and the VEGF-targeted tyrosine kinase inhibitor Inlyta (axitinib) improved overall survival and delayed cancer progression-free for patients with clear-cell metastatic renal cell carcinoma, compared to the current standard of care, Sutent (sunitinib).

About Keynote 426

In the study, 861 people with previously untreated clear-cell metastatic renal cell cancer were treated with either oral sunitinib once daily or to combination therapy, with pembrolizumab given intravenously every 3 weeks along with oral axitinib twice daily.

At a median follow-up of 12.8 months the combination therapy was associated with a 47% reduction in the risk of death compared with sunitinib. The 12-month overall survival rate was 89.9% in the combination group vs 78.3% in the sunitinib group and the benefit was seen irrespective of risk group or PD-L1 status.

Serious treatment-related side effects were reported in 62.9% of people on the combination therapy compared to 58.1% with sunitinib.



Copyright © 2019 CancerConnect. All Rights Reserved.